Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
about
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreDPP-4 inhibition and islet functionRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsThe evolving place of incretin-based therapies in type 2 diabetesProtein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Sex differences in type 2 diabetes: focus on disease course and outcomesSaxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian SubjectsDipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Therapeutic vaccine against DPP4 improves glucose metabolism in miceDipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.Is the GLP-1 system a viable therapeutic target for weight reduction?Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.A review of gliptins in 2011.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Pharmacokinetic study of saxagliptin in healthy Chinese subjects.Peptide Vaccines for Hypertension and Diabetes Mellitus.New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptinDapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
P2860
Q24569706-F4D6CA85-7B08-4213-A98F-5DD3BB3459D9Q27028127-7DEF2CEB-4D7A-445B-B1F8-F75AA2E7D6C8Q28081569-55FE7AC8-0E1D-4BF7-8B9D-308F8C8E705CQ33866808-3EDCDF28-2EB3-43A5-B46F-2AB5C8B9EBB1Q34135843-62BFE30A-007B-4856-91F3-9172C973DF6FQ34219918-15F9C8DC-B2B1-49AF-B398-F2E578283E7CQ34229975-8B27096A-70C3-4622-9351-6562FA52E59DQ35411329-73F7D71A-73BA-4BF5-878E-4E728A264539Q35998458-84BCE26E-23B0-4177-98B5-8BB5F6856F80Q36395003-3B14F63A-B249-449D-82C2-A19F67D39D9CQ37316259-BB000D8B-EE5D-4B87-A594-E41568000D40Q37687552-7B00C7F1-0DC9-47C5-BD38-1B16611CED21Q37735838-27FF19A5-326F-4222-8538-9DB2ABDD8049Q37760515-390BF118-9159-4F02-A62C-D5046BBF5492Q37845218-21A15089-6EBD-495E-A859-273BFEF3F4FEQ37890779-309B21E7-B3C6-4B94-8B3D-DA73C9B1DF19Q37965612-37A84CEF-12B5-4289-9DF3-9630F9FDC727Q38017726-80CEAE72-1151-45B1-A4DA-B89B8C46252FQ38058568-8796D9F0-4380-4DCC-9FE0-F5CBFCB7B4ADQ38152405-FC4A181F-923C-47F8-90D4-27206AFBBE30Q38200670-56FC4176-9B04-43E6-8E49-C28AABBD2FA0Q38470357-5C64ADA7-D01E-4302-B3D2-77782D9A7349Q38582135-0456FE7B-D462-44C5-876A-1CBB719AEE8AQ42058426-F5E708E1-FF9C-4983-96D3-A9CD07A155AEQ48015498-73F40D50-2031-4A20-B721-801025623E5A
P2860
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@en
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@nl
type
label
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@en
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@nl
prefLabel
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@en
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@nl
P1433
P1476
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
@en
P2888
P304
P356
10.1007/S12325-009-0030-9
P407
P577
2009-05-14T00:00:00Z